Engagement of the endogenous invariant TCR on iNKT cells can lead to killing of CD1d expressing tumor cells in the presence of αGalCer with or without co-expression of CAR target (61–64, 87), which could be relevant for CD1d expressing tumors including early stage myeloma (90), some B cell malignancies, marginal zone leukemia, mantle cell leukemia (64) and glioblastomas (91). Here, CD1D is linked to neoplasm.